

Human Cord Blood Mononuclear Cells Are Preferentially Infected by Non-Syncytium-Inducing, Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates

PETER P. REINHARDT,¹ BARBARA REINHARDT,¹ JANET L. LATHEY,¹
AND STEPHEN A. SPECTOR^{1,2*}

*Department of Pediatrics¹ and Center for Molecular Genetics,²
University of California, San Diego, La Jolla, California*

Received 8 July 1994/Returned for modification 20 October 1994/Accepted 7 November 1994

Identification of the factors which impact on the transmission of human immunodeficiency virus type 1 (HIV-1) from an infected mother to her infant is essential for the development of effective strategies to prevent perinatal HIV-1 infection. The current study was designed to determine if unstimulated human neonatal cord blood mononuclear cells (CBMC) differ from adult peripheral blood mononuclear cells (PBMC) in susceptibility to HIV-1 infection. Both cell populations were challenged with two laboratory and two clinical HIV-1 isolates with different phenotypic properties. Infection was evaluated by quantitation of p24 antigen production and p24 antigen expression by an enzyme immunoassay and immunofluorescence, respectively. T-cell markers were determined by flow cytometry. Unstimulated CBMC were preferentially infected by macrophage-tropic, non-syncytium-inducing (non-SI) laboratory and clinical isolates, whereas PBMC were more susceptible to T-lymphotropic, SI HIV-1 strains. The macrophage-tropic strain HIV-1_{Ba-L} replicated to 100-fold higher titers in CBMC than a similar inoculum of the SI isolate HIV-1_{LAI}. The opposite occurred in unstimulated PBMC, which replicated HIV_{LAI} to eightfold higher titers than the macrophage-tropic isolate. These findings indicate that a selection of viral phenotype may occur with unstimulated CBMC displaying a predominant susceptibility to infection by macrophage-tropic, non-SI HIV-1 strains and that this selection may influence mother-infant transmission of HIV-1.

Mother-infant transmission of human immunodeficiency virus type 1 (HIV-1) is an increasing problem worldwide. Perinatal transmission is estimated to occur in approximately 25% of infants born to HIV-1-infected mothers (7, 16, 22), with intrapartum transmission thought to occur more frequently than congenital infection (2-4). Information concerning the risk factors associated with mother-infant transmission is essential for the development of strategies designed to prevent perinatal HIV-1 infection. Advanced clinical disease, low counts of CD4⁺ lymphocytes, and elevated virus load in pregnant women are associated with enhanced risk of perinatal HIV-1 transmission (3). While some studies suggest that mothers with high titers of circulating anti-gp120 antibodies are less likely to transmit HIV-1 to their infants (1, 15, 23), others have not confirmed this correlation (14). Several recent studies suggest that selection of certain HIV-1 strains may occur during transmission. Zhu et al. have demonstrated that, during sexual transmission of HIV-1 between adults, selection for macrophage-tropic, non-syncytium-inducing (non-SI) isolates may occur (26). Similarly, Wolinsky et al. identified a minor subset of maternal virus that may preferentially infect the infant with no evidence for transmission of more prevalent genotypes (25). Thus, mother-infant HIV-1 transmission could involve in vivo selection for specific viral strains with distinctive biological phenotypes.

The physiologic immaturity of neonatal cells and the low level of lymphocyte activation in newborn infants are host factors that could influence infection of neonatal cells. Activated or memory CD4⁺ T cells that express the CD45RO

marker are much less frequent in the neonate, and they have been reported to be the major target cell type for HIV-1 infection (18). The studies described here were designed to compare the susceptibilities of unstimulated cord blood mononuclear cells (CBMC) and unstimulated adult peripheral blood mononuclear cells (PBMC) to infection with HIV-1 isolates of different phenotypes. Our findings suggest that CBMC can be preferentially infected with macrophage-tropic, non-SI HIV-1 strains and that this susceptibility may play a role in HIV-1 strains that are transmitted from an infected mother to her infant.

MATERIALS AND METHODS

Cell separation and culture conditions. Umbilical cords of full-term newborns born to HIV-1-seronegative mothers were cleaned of maternal blood, and cord blood samples were collected under sterile conditions by puncture of the umbilical vein. Peripheral blood samples were obtained from healthy, HIV-1-seronegative adults. CBMC and PBMC were separated from heparinized whole-blood samples by density centrifugation on Ficoll-Hypaque (Sigma Chemical Co., St. Louis, Mo.). The isolated mononuclear cells were washed twice in sterile phosphate-buffered saline (PBS) and once in RPMI 1640 (JRH Biosciences, Lenexa, Kans.) and maintained in RPMI 1640 supplemented with 20% heat-inactivated, low-endotoxin fetal bovine serum (JRH Biosciences), 1 mM L-glutamine, 100 U of penicillin per ml, and 1 µg of streptomycin per ml (basic medium). Neither phytohemagglutinin A (PHA) nor interleukin-2 was added to cells that were maintained unstimulated. In parallel, the same CBMC and PMBC samples were stimulated with PHA (3.5 mg/ml) (Sigma) in the basic medium described above for 48 h prior to infection. Unstimulated or stimulated cells were challenged with HIV-1 immediately following Ficoll-Hypaque gradient separation or PHA stimulation, respectively. Following HIV-1 infection, the unstimulated cells were maintained in basic medium while PHA-stimulated cells were maintained in basic medium supplemented with interleukin-2 (10 U/ml) (Boehringer Mannheim, Indianapolis, Ind.). At every harvest (see below), half of the medium was removed and replaced with the same fresh medium.

Cell viability was determined by trypan blue dye exclusion. Wright/Giemsa differential blood stains were performed on CBMC and PBMC samples imme-

* Corresponding author. Mailing address: Department of Pediatrics, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0672. Phone: (619) 534-7170. Fax: (619) 534-7411.

TABLE 1. Expression of T-cell subsets and T-cell maturation and activation markers on CBMC and adult PBMC^a

Treatment	CD4 ^b		CD45RA ^c		CD45RO ^c		CD25 ^c		CD69 ^c	
	CBMC	PBMC	CBMC	PBMC	CBMC	PBMC	CBMC	PBMC	CBMC	PBMC
None	47 ± 3.1	48 ± 9.3	90 ± 3.8	54 ± 7.4	13 ± 2.1	47 ± 6.1	4 ± 1.4	6 ± 1.8	1 ± 0.5	2 ± 0.7
PHA ^d	51 ± 1	54 ± 11.8	82 ± 4.4	42 ± 12	33 ± 2.5	62 ± 3.5	83 ± 1.2	39 ± 16	64 ± 12.8	50 ± 10.1
None ^e	48 ± 7.3	45 ± 8.3	83 ± 6.4	51 ± 4.8	13 ± 4	44 ± 5.7	5 ± 1	7 ± 2.7	2 ± 1	2 ± 0.5
HIV-1 _{LAI} ^e	40 ± 6.7	39 ± 8.7	80 ± 6.5	48 ± 7.4	17 ± 5.6	43 ± 9.1	4 ± 1.3	7 ± 1.2	1 ± 0.6	4 ± 1.2
HIV-1 _{Ba-L} ^e	45 ± 7.2	47 ± 9.3	79 ± 7	50 ± 9.6	14 ± 3.6	44 ± 8.4	4 ± 1.2	5 ± 0.8	1 ± 0.6	3 ± 1

^a The data are means and standard deviations for six samples.

^b Percent CD4⁺ lymphocytes among cells displaying forward and side scatter properties of lymphocytes.

^c Percent CD3⁺ cells.

^d Forty-eight-hour stimulation.

^e The data were obtained on day 3 after treatment.

diately after mononuclear-cell separation. Cultured cells were monitored by phase-contrast microscopy for cytopathic effect.

HIV-1 isolates. HIV-1-isolates were selected for these studies on the basis of their phenotypic properties in order to determine whether certain HIV-1 phenotypes would preferentially replicate in neonatal PBMC. HIV-1_{LAI}, a T-lymphotropic, high-replication, SI laboratory-adapted HIV-1 isolate, was obtained from the National Institutes of Health AIDS Research and Reference Reagent Program and expanded in CEM cells. HIV-1_{Ba-L}, a macrophage-tropic, low-replication, laboratory-adapted HIV-1 isolate, also was provided by the AIDS Reference Reagents Program and was expanded in monocyte-derived macrophages (9). HIV-1 clinical isolates were propagated and their phenotypes were characterized at the University of California, San Diego, Retrovirology Laboratory. Viruses were expanded in PHA-stimulated PBMC (6). One clinical isolate was high replication and T lymphotropic, induced syncytia in MT-2 cells, and did not infect monocyte-derived macrophages. This virus was isolated from a symptomatic patient with a CD4⁺ lymphocyte count of 153/mm³. The other clinical isolate was low replication, did not induce syncytia in MT-2 cells, and replicated well in primary monocyte-derived macrophages. This virus was isolated from a patient with a CD4⁺ lymphocyte count of 562/mm³. MT-2 cell assays were performed as previously described (20). All HIV-1 stocks were stored at -70°C as cell-free virus isolates after filtration through a 0.2-μm-pore-size filter. The tissue culture infective dose for each isolate was determined in PBMC or macrophages (HIV_{Ba-L}) as previously described (9, 11).

Susceptibility experiments. Unstimulated CBMC or unstimulated PBMC (5 × 10⁶) were incubated overnight with 5 × 10³ tissue culture infective doses of cell-free viral inoculum. Infection was performed in polypropylene tubes to prevent adherence of monocytes during viral exposure. After being washed five times with PBS, the cells were cultured either in 24-well flat-bottom tissue culture plates (Costar, Livermore, Calif.) or in 4-well tissue culture chamber slides (New England Nuclear, Boston, Mass.). The last wash was assayed for carryover p24 antigen. Supernatants were collected on days 3, 7, and 11 or 14 postinfection for quantitative p24 antigen detection (enzyme immunoassay; Abbott, Abbott Park, Ill.). Cultures were considered positive when increasing quantities of p24 antigen greater than 25 pg/ml were obtained on consecutive culture supernatants. Simultaneous infection of PHA-stimulated PBMC from a healthy adult donor was carried out to confirm the infectivity of viral stocks. All cultures were screened on days 3, 7, 10, and 14 for cytopathic effect by phase-contrast microscopy at a 100-fold magnification. Mock-infected cells from all CBMC and PBMC samples were cultured and evaluated as negative controls.

Flow cytometry. Representative unstimulated or PHA-stimulated CBMC and PBMC samples were stained with monoclonal antibodies to evaluate T-cell subset and activation parameters immediately prior to infection and 1 and 3 days after HIV-1 or mock infection. Two hundred thousand CBMC and PBMC were harvested, washed three times with sterile PBS, and resuspended in 10 μl of Hanks' balanced salt solution (without phenol red) containing 3% heat-inactivated fetal bovine serum, 0.1% sodium azide, and 10 mM HEPES (*N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid) (staining buffer) before selected concentrations of directly labelled antibodies were added. After incubation for 30 min at 4°C, cells were washed and resuspended in an ice-cold staining buffer. Human cell surface molecules and corresponding murine monoclonal antibodies were as follows: CD3, fluorescein isothiocyanate and phosphatidylethanolamine; CD45RA, fluorescein isothiocyanate; CD45RO, CD25, and CD69, phosphatidylethanolamine (Becton Dickinson, Mountain View, Calif.). To inactivate infectious virus, all CBMC and PBMC samples were fixed with 1% paraformaldehyde prior to analysis. Two-color flow cytometry employed a FACScan flow cytometer (Becton Dickinson) and LYSIS II research software. A total of 10⁴ events per sample were collected. Debris and dead cells were excluded by gating according to forward and side scatter properties.

Cell staining and immunofluorescence. CBMC and PBMC cultured in chamber slides were depleted of nonadherent cells by vigorous washing and evaluated

by nonspecific esterase, Wright/Giemsa staining, and immunostaining. For immunostaining, adherent cells were fixed in acetone-100% methanol and incubated with 10% human plasma (HIV seronegative) in PBS. Adherent cells were then incubated for 2 h with a mouse anti-HIV p24 antigen antibody (immunoglobulin G) (0.02 mg/ml) (DuPont, Boston, Mass.) and the Mo1 (Coulter, Hialeah, Fla.) mouse anti-CD11b (immunoglobulin M) (0.1 mg/ml) in PBS with 2% human plasma. After repeated washing with PBS, the fluorescein isothiocyanate-labelled rabbit-anti-mouse immunoglobulin G antibody (0.05 mg/ml) (Tago, Burlingame, Calif.) and the rhodamine-labelled goat anti-mouse immunoglobulin M antibody (0.05 mg/ml) (Chemicon, Los Angeles, Calif.) were added. The slides were washed after 30 min of incubation, mounted, and viewed with a Nikon Optiphot microscope.

RESULTS

Assessment of CBMC and PBMC populations. A total of 26 unstimulated CBMC samples and 15 unstimulated PBMC samples were analyzed for infectivity by the laboratory-adapted HIV-1 isolates HIV_{LAI} and HIV_{Ba-L}. Wright/Giemsa stains of the samples revealed normal blood differentials, with monocytes constituting 4 to 6% of the leukocyte populations in both cord blood samples and adult blood samples. After Ficoll-Hypaque separation of mononuclear cells, the viability was >98%, as determined by trypan blue dye exclusion, and the percentage of monocytes was 7 to 13% in both CBMC samples and PBMC samples; the remaining cells belonged almost exclusively to the lymphocyte population.

To characterize the differences between the fetal and adult mononuclear-cell samples, flow-cytometric analysis was performed on six CBMC and six PBMC samples with and without PHA stimulation. Samples were also analyzed before and after challenge with either HIV_{LAI} or HIV_{Ba-L} (Table 1). The distribution of T-cell subsets and T-cell maturation and activation parameters was assessed before and after HIV-1 infection. The levels of CD4⁺ T cells for CBMC and PBMC samples were similar. The majority (mean ± standard deviation, 90% ± 3.8%) of cord blood T cells expressed CD45RA (naive subset), while only 13% ± 2.1% expressed CD45RO (memory subset) molecules on their surface. In contrast, T cells in the PBMC samples had a higher concentration of CD45RO cells (47% ± 6.1%) with an almost equal division between memory and naive T cells (Table 1). Three days after infection with HIV-1, no significant difference in CD4⁺ T-cell levels was observed either between infected and uninfected cultures or between CBMC and PBMC cultures. Stimulating CBMC or PBMC with PHA for 48 h substantially increased the CD45RO⁺ population, as well as CD25 and CD69 (T-cell activation markers) expression (Table 1), signifying that both populations were competent for activation. To determine if T-cell activation of unstimulated cells occurs during the period of HIV-1 exposure,




FIG. 1. The rates of virus replication measured by p24 antigen production of three representative CBMC (A and B) and PBMC (C and D) samples, both unstimulated and stimulated, infected with either HIV_{LAI} (A and C) or HIV_{Ba-L} (B and D). Cell sample pairs are identified by identical symbols. Solid and open symbols, unstimulated and PHA-stimulated cell samples, respectively. Note that the linear scales for p24 antigen production differ by a factor of 10, reflecting the large differences in p24 antigen production in CBMC and PBMC infected with HIV_{LAI} or HIV_{Ba-L}.

the expression of CD25 and CD69 was evaluated before and after challenge with virus as well as 3 days postinfection. No significant upregulation of CD25 or CD69 in the CBMC and PBMC samples was observed, indicating that T-cell activation had not occurred during acute infection with HIV-1 (Table 1). Thus, the major difference between CBMC and PBMC was the reduced numbers of memory T cells in CBMC.

CBMC and PBMC differ in HIV-1 susceptibility and the rate of replication of HIV. To investigate differences in HIV-1 susceptibility between CBMC and PBMC, unstimulated cultures were challenged with either HIV_{LAI} or HIV_{Ba-L}, and p24 antigen was measured from the supernatant at 3, 7, and 14 days postinfection. Whereas HIV_{Ba-L} preferentially replicated in CBMC, HIV_{LAI} replicated to high levels in PBMC (Fig. 1).

All 26 (100%) unstimulated CBMC samples were infected by the macrophage-tropic isolate HIV_{Ba-L}, whereas the lymphotropic isolate HIV_{LAI} replicated in only 18 (69%) of 26 challenged CBMC samples. In contrast, while all 15 unstimulated PBMC samples replicated HIV_{LAI}, only 11 (73%) of 15 were susceptible to infection by HIV_{Ba-L}. There was a significant difference between these two cell populations in suscep-

tibility to infection by HIV_{LAI} and HIV_{Ba-L} ($P = 0.003$; χ^2). Of the 26 CBMC samples that were challenged with the two HIV-1 isolates, 24 (92%) HIV-1_{Ba-L}-infected samples produced 10- to 50-fold higher p24 antigen levels than the HIV-1_{LAI}-infected CBMC. The remaining two CBMC samples did not exhibit a difference in the ability to replicate either virus. The opposite was found for the unstimulated PBMC population, in which 14 (93%) of 15 samples showed enhanced replication of the isolate HIV_{LAI}, with three- to fivefold-higher p24 antigen levels than the levels for infection with HIV_{Ba-L} (Table 2). The one remaining PBMC sample did not display a difference in the ability to replicate either virus. Thus, CBMC were preferentially infected by macrophage-tropic isolates, while PBMC were more susceptible to infection by lymphotropic HIV-1 isolates.

Replication of clinical isolates of different phenotypes in CBMC and PBMC cultures. To determine if selective susceptibility to infection was also observed with clinical isolates, six unstimulated CBMC samples and six unstimulated PBMC samples were challenged with two clinical isolates of previously established phenotypes. One clinical isolate was high replica-

TABLE 2. Susceptibilities and rates of replication of HIV-1_{LAI} and HIV-1_{Ba-L} in unstimulated CBMC and adult PBMC

Cells	Susceptibility ^a to:		Replication ^b of:	
	HIV-1 _{LAI}	HIV-1 _{Ba-L}	HIV-1 _{LAV}	HIV-1 _{Ba-L}
CBMC	18/26 (69)	26/26 (100)	31 ± 9	838 ± 224
PBMC	15/15 (100)	11/15 (73)	241 ± 84	70 ± 23

^a Number of HIV-1-infected cell samples/total number of samples 14 days after challenge with HIV-1_{LAI} and HIV-1_{Ba-L}. Percentages are given in parentheses.

^b Nanograms of HIV-1 p24 antigen per ml of culture supernatant 14 days postinfection. The data are means and standard errors.

tion, T lymphotropic, and SI, while the other was low replication, macrophage-tropic, and non-SI. As in the experiments with the laboratory HIV-1 isolates, a higher susceptibility of unstimulated CBMC was found for the macrophage-tropic clinical HIV-1 isolate, which infected four (67%) of six samples, while the SI, T-cell-tropic clinical isolate replicated in only one (17%) of six CBMC samples. The reverse was observed with the PBMC cultures, in which the SI, T-cell-tropic clinical isolate produced high levels of p24 antigen in five (83%) of six samples and the macrophage-tropic isolate failed to replicate in any of the six unstimulated PBMC samples. Thus, the same dichotomy of infection that was observed with laboratory strains was also observed with clinical isolates.

PHA stimulation increases the replication of HIV-1 in CBMC. PHA stimulation is known to affect T-cell maturation and activation (13). Because we observed that the maturation and activation markers CD45RO, CD25, and CD69 were increased in both CBMC and PBMC following PHA stimulation, we studied whether PHA stimulation of cells would alter the HIV susceptibility pattern. For these experiments six PHA-stimulated and unstimulated CBMC and PBMC samples were concomitantly challenged with HIV_{LAI} or HIV_{Ba-L}. HIV_{LAI} infected 100% of unstimulated PBMC, with replication being increased 10- to 40-fold following PHA stimulation by day 14 (Fig. 1). While only four of six unstimulated CBMC samples could be infected with HIV_{LAI}, PHA stimulation resulted in 100% infectivity of samples. The rate of replication of HIV_{LAI} in CBMC was also influenced by PHA stimulation, with a 100-fold increase in viral replication observed by day 14. The impact of PHA stimulation was less dramatic in HIV_{Ba-L}-challenged cell samples, leading primarily to accelerated infection kinetics (Fig. 1). No increase in susceptibility in stimulated PBMC challenged with HIV_{Ba-L} was observed, with only four of six PBMC samples being susceptible to infection, regardless of stimulation. All unstimulated CBMC samples were infectable with HIV_{Ba-L}; therefore, the influence of PHA on CBMC susceptibility to this virus could not be determined.

HIV_{Ba-L} causes cytopathic effects in adherent unstimulated CBMC. The morphology of HIV-1-infected and mock-infected CBMC and PBMC samples was examined during the 14 days of culture. Within 2 to 5 days, a monolayer of adherent cells was observed, consisting of rounded as well as spindle-shaped cells. Multinucleated giant cells developed among the adherent cells of cord blood samples within 7 days of challenge with HIV_{Ba-L} and reached 20 to 50% of adherent cells by 14 days postinfection with the macrophage-tropic isolate. No cytopathic changes were seen in HIV_{LAI}-challenged or mock-infected CBMC samples or among the adherent cells of the adult blood samples, regardless of viral challenge (Fig. 2).

To determine the predominant cell type of adherent cells in CBMC and PBMC cultures, nonspecific esterase staining and

immunofluorescence staining against the macrophage epitope CD11b were performed. Adherent cells from HIV-1-challenged unstimulated CBMC and PBMC cultured on chamber slides were also evaluated for HIV-1 p24 antigen expression. More than 98% of adherent cells of the uninfected control CBMC and PBMC samples were esterase positive, and more than 80% stained positive with CD11b, while p24 antigen was undetectable in these samples. Positive staining for p24 antigen was not observed in adherent cells of CBMC or PBMC challenged with HIV_{LAI}, while the staining pattern for CD11b was similar to that for the mock-infected control. After challenge with HIV_{Ba-L}, PBMC remained negative for intracytoplasmatic p24 antigen. However, 30 to 50% of the adherent CBMC stained positive for p24 antigen, and viral-protein-containing cells were mainly multinucleated giant cells that also stained positive for esterase and CD11b (data not shown). Thus, the adherent CBMC producing HIV-1 were predominantly macrophages.

DISCUSSION

These results demonstrate an enhanced susceptibility of unstimulated CBMC to macrophage-tropic, non-SI HIV-1 isolates, while unstimulated adult PBMC were more readily infected by T-lymphotropic, SI isolates. Moreover, unstimulated CBMC were more susceptible to infection by macrophage-tropic strains than were PBMC and allowed for significantly higher viral replication as reflected by higher release of p24 antigen into culture supernatants. Additionally, HIV-1_{Ba-L}-infected adherent CBMC demonstrated intracytoplasmic staining for p24 antigen, while no such staining was observed in adherent CBMC challenged with HIV-1_{LAI}. The high p24 antigen production in HIV-1_{Ba-L}-infected CBMC was accompanied by adherent multinucleated giant cells, which were not observed in the HIV-1-infected PBMC. The reasons for differences in susceptibility between CBMC and PBMC are unclear. The discrepancy in susceptibility to macrophage-tropic HIV-1 isolates cannot be explained by differences in the percentages of monocytes in CBMC and PBMC, which were equivalent in both sources of cells. It is possible that interactions between cord blood T cells and monocytes may lead to production of cytokines that differ from those seen with adult PBMC. Previous *in vitro* studies have shown that gamma interferon can down regulate viral replication in monocytes/macrophages (8). In this regard, the markedly lower gamma interferon production of neonatal CD4⁺ and CD8⁺ T cells compared with analogous adult T cells (10) may explain, in part, the significantly higher levels of HIV-1 in CBMC cultures after infection with HIV_{Ba-L}.

Recently Ho et al. (5) described higher replication of laboratory-adapted, macrophage-tropic HIV-1 isolates in cord blood-derived adherent macrophages compared with macrophages derived from adult peripheral blood. Similarly, Sperduto et al. have recently shown that differentiated CBMC-derived macrophages are more susceptible to both macrophage-tropic and T-lymphotropic strains of HIV-1 (21). However, there are important differences between these studies and our present study. In these reports (5), cord blood monocytes were adhered and differentiated into macrophages before challenge with HIV-1, thus making them more susceptible to HIV-1 infection. In the current study, in order to more closely assess the susceptibility of circulating neonatal cells to HIV-1 infection, unstimulated CBMC were challenged with HIV-1 without prior differentiation of cells. Therefore, high levels of undifferentiated monocytes and naive, nonactivated T cells (high CD45RA⁺, low CD25⁺) were exposed to infection by HIV-1.




FIG. 2. Phase-contrast microscopy of adherent CBMC and PBMC on day 14 postinfection. (A) Uninfected adherent CBMC. (B) HIV-1_{LAI}-challenged adherent CBMC. Adherent cells are indistinguishable from uninfected CBMC; no multinucleated giant cells can be observed. (C) HIV-1_{Ba-L}-infected adherent CBMC. Multinucleated giant cells with typical marginalized localization of nuclei represent 20 to 50% of adherent cells. (D) Uninfected adherent PBMC. (E) HIV-1_{LAI}-challenged adherent PBMC. Adherent cells are indistinguishable from uninfected PBMC. (F) HIV-1_{Ba-L}-infected adherent PBMC. Compared with CBMC, cytopathic effect cannot be observed in the HIV-1_{Ba-L}-challenged adherent PBMC. Magnification, $\times 200$.

In parallel to the enhanced susceptibility of unstimulated CBMC to HIV_{Ba-L}, CBMC were less permissive to infection and replication of the lymphotropic, SI isolate HIV_{LAI} than PBMC. The difference in lymphocyte maturation between neonatal and adult cells could explain these findings, whereas flow-cytometric analysis before and after infection with HIV_{LAI} did not reveal differences in CD4⁺ T-cell levels or rates of CD4⁺ cell depletion. Only a minority of neonatal T cells express CD45RO, the memory subset marker, whereas 50 to 60% of adult T cells belong to the memory T-cell subset. Furthermore, PHA stimulation of CD45RA⁺ T cells leads to activation with increased CD25 expression and conversion to CD45RO⁺ T cells and, thus, to an increased susceptibility to HIV-1 infection. Therefore, addition of T-cell-activating stimuli (i.e., PHA) abolished the difference in HIV-1 susceptibility and the rate of replication between CBMC and PBMC. A difference in intrinsic cell properties (19, 24), such as the state of activation or differentiation, may be responsible for these observations.

The enhanced susceptibility of CBMC to infection with macrophage-tropic isolates suggests that a selective process in favor of such isolates might be involved in mother-infant transmission. Moreover, the finding of HIV-1-infected macrophages in the cervix of infected women (12) is of interest, because transmission of HIV-1 may occur during vaginal delivery when comes in contact with a non-SI, macrophage-tropic HIV-1 strain. Our laboratory and others have recently reported that perinatally infected infants are predominantly infected by non-SI strains of HIV-1 (17, 20). Of interest is that, in contrast to adults, among whom those infected with non-SI

strains of HIV-1 usually have slowly progressive disease, infants infected with non-SI variants can rapidly develop AIDS within the first year of life (20).

In summary, we have found that unstimulated CBMC are more susceptible to productive infection with macrophage-tropic, non-SI HIV-1 strains than are adult PBMC and that SI, T-lymphotropic virus more readily infects adult PBMC than neonatal cells. These data support the hypothesis that certain viral phenotypes of HIV-1 may be preferentially transmitted from an infected mother to her infant and that these phenotypes may replicate more efficiently in infants than in similarly infected adults. Further studies will be required to support these hypotheses.

ACKNOWLEDGMENTS

This study was supported in part by grants (AI-27563, AI-27670, and AI-36214) from the National Institutes of Health. B. Reinhardt was supported by a Fogarty international training grant for AIDS research, and P. Reinhardt was supported by the Deutsche Forschungsgemeinschaft.

REFERENCES

- DeVash, Y., T. A. Calvetti, D. G. Wood, K. J. Reagan, and A. Rubenstein. 1990. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. *Proc. Natl. Acad. Sci. USA* **87**:3445-3449.
- Ehrnst, A., S. Lindgren, M. Dictor, B. Johansson, A. Sonnerborg, J. Czajkowski, G. Sundin, and A. B. Bohlin. 1991. HIV in pregnant women and their offspring: evidence for late transmission. *Lancet* **338**:203-207.
- European Collaborative Study. 1992. Risk factors for mother-to-child transmission of HIV. *Lancet* **338**:1007-1012.
- Goedert, J. J., A. M. Duliege, C. J. Amos, S. Felton, and R. J. Biggar. 1991.

- The international registry of HIV-exposed twins. High risk of HIV-1 infection in first-born twins. *Lancet* **338**:1471-1475.
5. **Ho, W.-Z., J. Lioy, L. Song, J. R. Cutilli, R. A. Polin, and S. D. Douglas.** 1992. Infection of cord blood monocyte-derived macrophages with human immunodeficiency virus type 1. *J. Virol.* **66**:573-579.
 6. **Hollinger, F. B., J. W. Bremer, L. E. Myers, J. W. M. Gold, L. McQuay, and the NIH/NIAID/DAIDS/ACTG Virology Laboratories.** 1992. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. *J. Clin. Microbiol.* **30**:1787-1794.
 7. **Italian Multicenter Study.** 1988. Epidemiology, clinical features, and prognostic factors of paediatric HIV infection. *Lancet* **i**:1043-1045.
 8. **Kornbluth, R. S., P. S. Oh, J. R. Munis, P. H. Cleveland, and D. D. Richman.** 1989. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. *J. Exp. Med.* **169**:1137-1151.
 9. **Lathey, J. L., D. H. Spector, and S. A. Spector.** 1994. Human cytomegalovirus-mediated enhancement of human immunodeficiency virus type-1 production in monocyte-derived macrophages. *Virology* **199**:98-104.
 10. **Lewis, D. B., C. C. Yu, J. Meyer, B. K. English, S. J. Kahn, and C. B. Wilson.** 1991. Cellular and molecular mechanisms for reduced interleukin 4 and interferon- γ production by neonatal T cells. *J. Clin. Invest.* **87**:194-202.
 11. **Ogino, M. T., W. M. Dankner, and S. A. Spector.** 1993. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. *J. Pediatr.* **123**:1-8.
 12. **Pomerantz, R. J., S. M. De La Monte, S. P. Donegan, T. R. Rota, M. W. Vogt, D. E. Craven, and M. S. Hirsch.** 1988. Human immunodeficiency virus (HIV) infection of the uterine cervix. *Ann. Intern. Med.* **108**:321-327.
 13. **Rich, E. A., I. S. Y. Chen, J. A. Zack, M. L. Leonard, and W. A. O'Brien.** 1992. Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). *J. Clin. Invest.* **89**:176-183.
 14. **Robertson, C. A., J. Y. Q. Mok, K. S. Froebel, P. Simmonds, S. M. Burns, H. S. Marsden, and S. Graham.** 1992. Maternal antibodies to gp120 V3 sequence do not correlate with protection against vertical transmission of human immunodeficiency virus. *J. Infect. Dis.* **166**:704-709.
 15. **Rossi, P., V. Moschese, P. A. Broliden, C. Fundaro, I. Quinti, A. Plebani, C. Giaquinto, P. A. Tovo, K. Ljunggren, and J. Rosen.** 1989. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. *Proc. Natl. Acad. Sci. USA* **86**:8055-8058.
 16. **Ryder, R. W., W. Nsa, S. E. Hassig, F. Behets, M. Rayfield, B. Ekongola, A. M. Nelson, U. Mulenda, H. Francis, and K. Mwandagaliwa.** 1989. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. *N. Engl. J. Med.* **320**:1637-1642.
 17. **Scarlatti, G., V. Hodara, P. Rossi, L. Muggiasca, A. Bucciari, J. Albert, and E. M. Fenyo.** 1993. Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. *Virology* **197**:624-629.
 18. **Schnittman, S. M., H. C. Lane, J. Greenhouse, J. S. Justement, M. Baseler, and A. S. Fauci.** 1990. Preferential infection of CD4⁺ memory cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. *Proc. Natl. Acad. Sci. USA* **87**:6058-6062.
 19. **Schuitmaker, H., N. A. Kootstra, M. H. Koopelman, S. M. Bruisten, H. G. Huisman, M. Tersmette, and F. Miedema.** 1992. Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. *J. Clin. Invest.* **89**:1154-1160.
 20. **Spencer, L. T., M. T. Ogino, W. M. Dankner, and S. A. Spector.** 1994. Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children. *J. Infect. Dis.* **169**:491-495.
 21. **Sperduto, A. R., Y. J. Bryson, and I. S. Y. Chen.** 1993. Increased susceptibility of neonatal monocyte/macrophages to HIV-1 infection. *AIDS Res. Hum. Retroviruses* **9**:1277-1285.
 22. **The European Collaborative Study.** 1988. Mother-to-child transmission of HIV infection. *Lancet* **i**:1039-1043.
 23. **Ugen, K. E., J. J. Goedert, J. Boyer, Y. Rafaei, I. Frank, W. V. Williams, A. Willoughby, S. Landesman, H. Mendez, and A. Rubinstein.** 1992. Vertical transmission of human immunodeficiency virus (HIV) infection: reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. *J. Clin. Invest.* **89**:1923-1930.
 24. **Valentin, A., S. Matsuda, and B. Asjo.** 1990. Characterization of the in vitro maturation of monocytes and the susceptibility to HIV infection. *AIDS Res. Hum. Retroviruses* **6**:977-978.
 25. **Wolinsky, S. M., C. M. Wike, B. T. M. Korber, C. Hutto, W. P. Parks, L. L. Rosenblum, K. J. Kunstman, M. R. Furtado, and J. L. Munoz.** 1992. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. *Science* **255**:1134-1137.
 26. **Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho.** 1993. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. *Science* **261**:1179-1181.